drugset / Trial / NCT00145431

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.

NCT00145431

Phase 3 Terminated 41 enrolled Pfizer
RandomizedCrossoverDouble-blindTreatment

Summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug torcetrapib/atorvastatin in subjects with a rare genetically known disorder of high cholesterol and triglyceride levels.

Timeline

Start
2005-03
Primary completion
2006-12
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule
Subject Fenofibrate Small molecule
Subject torcetrapib Small molecule